Antibiotics mm13902

Claim 1

A pharmaceutical composition for treating bacterial infections in humans and animals which comprises an antibacterially effective amount of a pharmaceutically acceptable di-basic salt of MM 13902 which is at least 50% pure wherein MM 13902 is a solid carboxylic acid of the molecular formula C 13 H 16 O 8 N 2 S 2 which in the form of a substantially pure sodium salt has the following characteristics: (a) in aqueous solution, it has a characteristic ultraviolet spectrum with absorption maxima at about 305 nm and at about 225 nm substantially as shown in FIG. 1; (b) when present at 0.4% w/w in a freshly prepared KBr disc, it has a characteristic infra-red spectrum which has absorption maxima at inter alia about 3450, 2950, 1750, 1620, 1510, 1400 and 1260 cm -1 ; (c) it has a characteristic N.M.R. spectrum when taken in D 2 O which spectrum possesses inter alia (i) a pair of low field doublets centered at approximately 2.85t and 4.00t with coupling constants of approximately 14 Hz; (ii) a doublet centered at approximately 8.55t and (iii) a sharp singlet at approximately 8.00t; (d) it possesses antibacterial activity against various species including, inter alia, strains of Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Salmonella typhi and Pseudomonas aeruginosa; and (e) when mixed with ampicillin it synergizes its activity against organisms including strains of Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Proteus morganii and Staphylococcus aureus Russell, in combination with a pharmaceutically acceptable carrier.

Claim 13

A method of treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof an antibacterially effective amount of a pharmaceutical composition which comprises an antibacterially effective amount of a pharmaceutically acceptable di-basic salt of MM 13902 which is at least 50% pure wherein MM 13902 is a solid carboxylic acid of the molecular formula C 13 H 16 O 8 N 2 S 2 which in the form of a substantially pure sodium salt has the following characteristics: (a) in aqueous solution, it has a characteristic untraviolet spectrum with absorption maxima at about 305 nm and at about 225 nm substantially as shown in FIG. 1; (b) when present at 0.4% w/w in a freshly prepared KBr disc, it has a characteristic infra-red spectrum which has absorption maxima at inter alia about 3450, 2950, 1750, 1620, 1510, 1400 and 1260 cm -1 ; (c) it has a characteristic N.M.R. spectrum when taken in D 2 O which spectrum possesses, inter alia, (i) a pair of low field doublets centered at approximately 2.85t and 4.00t with coupling constants of approximately 14 Hz; (ii) a doublet centered at approximately 8.55t and (iii) a sharp singlet at approximately 8.00t; (d) it possesses antibacterial activity against various species including, inter alia, strains of Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Salmonella typhi and Pseudomonas aeruginosa; and (e) when mixed with ampicillin it synergizes its activity against organisms including strains of Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Proteus morganii and Staphylococcus aureus Russell, in combination with a pharmaceutically acceptable carrier.

Claim 14

A method of treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof an antibacterially effective amount of a pharmaceutical composition which comprises an antibacterially effective amount of a pharmaceutically acceptable di-basic salt of MM 13902 which is at least 50% pure wherein MM 13902 is a solid carboxylic acid of the molecular formula C 13 H 16 O 8 N 2 S 2 which in the form of a substantially pure sodium salt has the following characteristics: (a) in aqueous solution, it has a characteristic untraviolet spectrum with absorption maxima at about 305 nm and at about 225 nm substantially as shown in FIG. 1; (b) when present at 0.4% w/w in a freshly prepared KBr disc, it has a characteristic infra-red spectrum which has absorption maxima at inter alia about 3450, 2950, 1750, 1620, 1510, 1400 and 1260 cm -1 ; (c) it has a characteristic N.M.R. spectrum when taken in D 2 O which spectrum possesses, inter alia, (i) a pair of low field doublets centered at approximately 2.85t and 4.00t with coupling constants of approximately 14 Hz; (ii) a doublet centered at approximately 8.55t and (iii) a sharp singlet at approximately 8.00t; (d) it possesses antibacterial activity against various species including, inter alia, strains of Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Salmonella typhi and Pseudomonas aeruginosa; and (e) when mixed with ampicillin it synergizes its activity against organisms including strains of Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Proteus morganii and Staphylococcus aureus Russell, in combination with a pharmaceutically acceptable carrier.